Skip to Content
Merck

HT110232

Eosin Y Solution, Aqueous

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

NACRES:
NA.47
UNSPSC Code:
41116124
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

form

solution

shelf life

Expiry date on the label.

IVD

for in vitro diagnostic use

concentration

0.5 % (w/v) in water

application(s)

hematology
histology

storage temp.

room temp

Quality Level

Looking for similar products? Visit Product Comparison Guide

Other Notes

Certified Eosin Y, 0.5% (w/v) in water. Not acidified.

Application

General purpose cytoplasmic counterstain. Used with hematoxylin and eosin staining.

Storage Class

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Oliver Hachmöller et al.
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 44, 71-75 (2017-10-03)
The influence of rhodanine and haematoxylin and eosin (HE) staining on the copper distribution and concentration in liver needle biopsy samples originating from patients with Wilson's disease (WD), a rare autosomal recessive inherited disorder of the copper metabolism, is investigated.
Wei-Ting Chen et al.
Cell, 182(4), 976-991 (2020-07-24)
Although complex inflammatory-like alterations are observed around the amyloid plaques of Alzheimer's disease (AD), little is known about the molecular changes and cellular interactions that characterize this response. We investigate here, in an AD mouse model, the transcriptional changes occurring
Lucía Barbier-Torres et al.
Nature communications, 11(1), 3360-3360 (2020-07-06)
Nonalcoholic fatty liver disease (NAFLD) is considered the next major health epidemic with an estimated 25% worldwide prevalence. No drugs have yet been approved and NAFLD remains a major unmet need. Here, we identify MCJ (Methylation-Controlled J protein) as a
Marshall W Hogarth et al.
Nature communications, 8, 14143-14143 (2017-02-01)
Duchenne muscular dystrophy (DMD) is characterized by muscle degeneration and progressive weakness. There is considerable inter-patient variability in disease onset and progression, which can confound the results of clinical trials. Here we show that a common null polymorphism (R577X) in
Ann-Britt Marcher et al.
Scientific reports, 9(1), 2324-2324 (2019-02-23)
Non-alcoholic steatohepatitis (NASH) signified by hepatic steatosis, inflammation, hepatocellular injury, and fibrosis is a growing cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma. Hepatic fibrosis resulting from accumulation of extracellular matrix proteins secreted by hepatic myofibroblasts plays an important

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service